CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas

Cancer Research

Volumn 65, Issue 3, 2005, Pages 828-834

  Abe, Masanobu ^a,b   Ohira, Miki ^c   Kaneda, Atsushi ^a   Yagi, Yukiko ^a   Yamamoto, Seiichiro ^d   Kitano, Yoshihiro ^e   Takato, Tsuyoshi ^b   Nakagawara, Akira ^c   Ushijima, Toshikazu ^a,f  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Cancer Research Institute   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; NEUROBLASTOMA; ONCOGENE C MYB; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; CHILD, PRESCHOOL; CPG ISLANDS; DNA METHYLATION; GENOME, HUMAN; HUMANS; INFANT; INFANT, NEWBORN; NEUROBLASTOMA; PLOIDIES; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 13444270332     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
2. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93.
3. Kondo Y, Kanai Y, Sakamoto M, et al. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000;32:970-9.
4. Ushijima T, Morimura K, Hosoya Y, et al. Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci U S A 1997;94:2284-9.
5. Kaneda A, Takai D, Kaminishi M, Okochi E, Ushijima T. Methylation-sensitive representational difference analysis and its application to cancer research. Ann N Y Acad Sci 2003;983:131-41.
6. Takai D, Yagi Y, Wakazono K, et al. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene 2001;20:7505-13.
7. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002;62:6645-50.
8. Miyamoto K, Asada K, Fukutomi T, et al. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 2003;22:274-80.
9. Hagihara A, Miyamoto K, Furuta J, et al. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004;23:8705-10.
10. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev. Cancer 2003;3:203-16.
11. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80.
12. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54.
13. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245-54.
14. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002;3:662-73.
15. Kaneda A, Kaminishi M, Sugimura T, Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett 2004;212:203-10.
16. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-6.
17. Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998;58:1245-52.
18. Nguyen C, Liang G, Nguyen TT, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 2001;93:1465-72.
19. Ushijima T, Watanabe N, Okochi E, et al. Fidelity of the methylation pattern and its variation in the genome. Genome Res 2003;13:868-74.
20. Yamashita K, Dai T, Dai Y, Yamamoto F, Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 2003;4:121-31.
21. Agathanggelou A, Dallol A, Zochbauer-Muller S, et al. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene 2003;22:1580-8.
22. Takita J, Hayashi Y, Nakajima T, et al. The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene 1998;17:3137-43.
23. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-9.
24. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004;24:4781-90.
25. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002;108:489-500.